MedTrace Logo

A Study of Lurasidone HCl in Subjects With Schizophrenia

NCT03393026 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2020-02-05

No results posted yet for this study

Summary

The study evaluates the effectiveness and safety of Lurasidone in subjects with schizophrenia over a period of 6 weeks.

Conditions

Interventions

DRUG

Lurasidone

Lurasidone 40-160 mg/day for 6 weeks

Sponsors & Collaborators

  • Standard Chem. & Pharm. Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-03
Primary Completion
2019-09-17
Completion
2019-09-17

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03393026 on ClinicalTrials.gov